Cargando…
Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background
Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022196/ https://www.ncbi.nlm.nih.gov/pubmed/21253480 http://dx.doi.org/10.4061/2011/798658 |
_version_ | 1782196481232470016 |
---|---|
author | Rigolli, Marzia Cicoira, Mariantonietta Bergamini, Corinna Chiampan, Andrea Rossi, Andrea Vassanelli, Corrado |
author_facet | Rigolli, Marzia Cicoira, Mariantonietta Bergamini, Corinna Chiampan, Andrea Rossi, Andrea Vassanelli, Corrado |
author_sort | Rigolli, Marzia |
collection | PubMed |
description | Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to assess whether genetic background of maximally treated CHF patients predicts variations in LV systolic function and volumes. Methods and Results. We prospectively studied 131 CHF outpatients on optimal treatment for at least six months. Echocardiographic evaluations were performed at baseline and after 12 months. Genotype analysis for ACE I/D, β1adrenergic receptor (AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu polymorphisms was performed. No differences in baseline characteristics were detected among subgroups. ACE II was a significant predictor of improvement of LV end-diastolic and end-systolic volume (P = .003 and P = .002, respectively) but not of LV ejection fraction (LVEF); β1AR389 GlyGly was related to improvement of LVEF (P = .02) and LV end-systolic volume (P = .01). The predictive value of polymorphisms remained after adjustment for other clinically significant predictors (P < .05 for all). Conclusions. ACE I/D and β1AR Arg389Gly polymorphisms are independent predictors of reverse remodeling and systolic function recovery in CHF patients under optimal treatment. |
format | Text |
id | pubmed-3022196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-30221962011-01-20 Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background Rigolli, Marzia Cicoira, Mariantonietta Bergamini, Corinna Chiampan, Andrea Rossi, Andrea Vassanelli, Corrado Cardiol Res Pract Research Article Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to assess whether genetic background of maximally treated CHF patients predicts variations in LV systolic function and volumes. Methods and Results. We prospectively studied 131 CHF outpatients on optimal treatment for at least six months. Echocardiographic evaluations were performed at baseline and after 12 months. Genotype analysis for ACE I/D, β1adrenergic receptor (AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu polymorphisms was performed. No differences in baseline characteristics were detected among subgroups. ACE II was a significant predictor of improvement of LV end-diastolic and end-systolic volume (P = .003 and P = .002, respectively) but not of LV ejection fraction (LVEF); β1AR389 GlyGly was related to improvement of LVEF (P = .02) and LV end-systolic volume (P = .01). The predictive value of polymorphisms remained after adjustment for other clinically significant predictors (P < .05 for all). Conclusions. ACE I/D and β1AR Arg389Gly polymorphisms are independent predictors of reverse remodeling and systolic function recovery in CHF patients under optimal treatment. SAGE-Hindawi Access to Research 2011-01-05 /pmc/articles/PMC3022196/ /pubmed/21253480 http://dx.doi.org/10.4061/2011/798658 Text en Copyright © 2011 Marzia Rigolli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rigolli, Marzia Cicoira, Mariantonietta Bergamini, Corinna Chiampan, Andrea Rossi, Andrea Vassanelli, Corrado Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
title | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
title_full | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
title_fullStr | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
title_full_unstemmed | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
title_short | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
title_sort | progression of left ventricular dysfunction and remodelling under optimal medical therapy in chf patients: role of individual genetic background |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022196/ https://www.ncbi.nlm.nih.gov/pubmed/21253480 http://dx.doi.org/10.4061/2011/798658 |
work_keys_str_mv | AT rigollimarzia progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT cicoiramariantonietta progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT bergaminicorinna progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT chiampanandrea progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT rossiandrea progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT vassanellicorrado progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground |